DrugAlternative line
Etanercept
Soluble TNF receptor fusion protein (TNFR2-Fc)
- Response rate
- Partial, waning over time
- Onset
- Days–weeks
- Route
- SC 25mg twice weekly or 50mg weekly
- Line
- Alternative
- IgM effect
- N/A
- Evidence level
- amber
Evidence summary
Historically the first biologic used in TRAPS. NIH dose-escalation study (15 patients) showed dose-dependent symptom reduction but incomplete normalisation. Long-term efficacy wanes — median duration 3.3 years before switching. Now largely superseded by IL-1 agents. May still be considered where IL-1 agents are unavailable.
Approved indications
Conditions for which Etanercept has regulatory approval (not specific to rare diseases covered here):
Rheumatoid ArthritisAnkylosing SpondylitisPsoriasisJIA
Drug identifiers
| DrugBank | DB00005 ↗ |
| ATC Code | L04AB01 |
Molecular targets
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| TNF-α | Ligand for TNFR1 — upstream trigger | Elevated during attacks | established |